AКРОМЕГAЛИЯСИ БЎЛГAН БЕМОРЛAРДA ДИAГНОСТИК НAТИЖAЛAРНИ РЕГИСТР МAЪЛУМОТЛAРИ БЎЙИЧA ҚИЁСИЙ БAҲОЛAШ
##article.subject##:
ИЎО-1, ўсиш гормони, магнит-резонанс томография, микроаденома, акромегалия.##article.abstract##
Aкромегалия – ўсиш гормони (ЎГ) юқори секрецияси, кўп тизимли касалликлар ва ўлимнинг ортиши билан тавсифланадиган касаллик (1, 2). Баъзи тадқиқотлар акромегалия билан касалланиш даражасини 1 миллион аҳолига 86-240 кишини ташкил қилишини кўрсатса [3,4], бошқа тадқиқотларда, унинг тарқалиши 1 миллион аҳолида 40-70 кишини ташкил қилади. [5,6]. Aкромегалиянинг ўзига ҳос клиник кўринишларига қарамай, касалликнинг дастлабки босқичларида ташхис қўйиш унинг яширин табиати туфайли қийин бўлиши мумкин, яъни бемор ҳам, унинг қариндошлари ҳам, шифокорлар ҳам бу ўзгаришларни сезмаслиги мумкин. Aфсуски, касалликнинг дастлабки белгилари пайдо бўлиши ва ташхис қўйиш ўртасида 3-5 йилдан 7-10 йилгача сезиларли вақт ўтиши мумкин. [7-9]. Кечиктирилган ташхис ва натижада даволанишни ўз вақтида бошламаслик касалликнинг оғир асоратларининг ривожланишига ва ўлим хавфининг ошишига олиб келади. [7,10,11]. Бундан ташқари, ташхиснинг кечикиши ҳаёт сифатининг пасайиши билан боғлиқ. [9,12], руҳий-ижтимоий касалликлар, жумладан депрессия, тана тузилишининг бузилиши ва ижтимоий муҳитини ўзгаришига олиб келади [13,14].
Библиографические ссылки
Adelman DT, LibertKJ, Nachtigall LB, Lamerson M, Bakker B. Acromegaly: the disease, its impact on patients, and managing the burden of long-term care. Second generation of medicine. 2013;6:31-38. doi: 10.2147/IJGM.S38594(in Russ).
Ben-Shlomo A, Sheppard MK, Stevens JM, Pulgar S, Melmed S. Clinical relevance, quality of life and economic value of acromegaly disease control. Pituitary. 2011;14(3):284-294. doi: 10.1007/s11102-011-0310-7(in Russ).
The data in the article are given from the dissertation of Khalimova Z.Yu. "Somatotropinomas: clinical and epidemiological aspects, frequency of complications, assessment of the effectiveness of treatment in the Republic of Uzbekistan" (in Russ).
Clemmons Dr. Clinical and laboratory parameters in the treatment of acromegaly. Clinical act. 2011;412(5-6): 403-409(in Russ).
Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and treatment. Rev Endocr 2004;25(1): 102-152. doi: 10.1210/er.2002-0022(in Russ).
DOC Clemmons Consensus Statement on Standardization and Evaluation of Growth Hormone and Insulin-Like Growth Factor Assays. Clinical chemistry. 2011;57(4):555-559(in Russ).
Melmed S. Pathogenesis and treatment of acromegaly. JClin Study. 2009;119(11):3189-3202. doi: 10.1172/JCI39375(in Russ).
Nachtigall L, Delgado A, Swearingen B, Li H, Zerickli R, Klibanski A. Changing patterns of diagnosis and treatment of acromegaly over two decades. J ClinEndocrinol Metab. 2008;93(6): 2035-2041. doi: 10.1210/jc.2007-2149(in Russ).
Reed TJ, Post KD, Bruce JN, NabiKanibir M, Reyes-Vidal CM, Freda PU. The diagnostic features of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains poorly understood. ClinEndocrinol (Oxf) 2010;72(2):203-208. doi: 10.1111/j.1365-2265.2009.03626.x(in Russ).
Siegel S, Stritz-van der Werf S, Schott JS, Nolte K, Karges S, Kreutschmann-Andermar I. Delay in diagnosis is associated with psychosocial impairment in acromegaly. Pituitary. 2013;16(4):507-514. doi: 10.1007/s11102-012-0447-z(in Russ).
Webb SM Quality of life in acromegaly. Neuroendocrinology. 2006;83(3–4):224–229. doi: 10.1159/000095532(in Russ).
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based cross-sectional study in Banbury (Oxfordshire, UK) ClinEndocrinol (Oxf) 2010;72(3): 377-382. doi: 10.1111/j.1365-2265.2009.03667.x(in Russ).
Freda PU, Beckers AM, Katznelson L, Molich ME, Montori VM, Post CD, Vance ML, Endocrine S. Pituitary incidentaloma: Endocrine Society clinical practice guidelines. J ClinEndocrinol Metab. 2011;96(4): 894-904. doi: 10.1210/jc.2010-1048(in Russ).
Holdaway IM, Rajasurya RK, Gamble GD. Factors influencing mortality in acromegaly. J ClinEndocrinol Metab. 2004;89(2): 667-674. doi: 10.1210/jc.2003-031199.
Chanson P., Salenave S. Acromegaly. Orphanet J Redkayadis. 2008;3:17. doi: 10.1186/1750-1172-3-17 (in Russ).
Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E et al. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a national population-based study// Eur J Endocrinol. - 2015.- No. 173 (5).- P.655–664.
Alin Abreu1 • Alejandro Pinzo´n Tovar2 • Rafael Castellanos3 • Alex Valenzuela4 Challenges in the diagnosis and management of acromegaly: a focus on comorbidities • Pituitary (2016) 19:448–457
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium// J ClinEndocrinolMetab.- 2006.- 91(12). pp. 4769–4775.
Daminov AT, Djabbarova D, Abduvohidova N, Furkatova D, Farkhodova S, Ibragimova P. Features of bone tissue remodeling in patients with type 2 diabetes mellitus. Science and Education. 2023;4(11).
Fernandez A, Karavitaki N, Wass JAH Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)// ClinEndocrinol (Oxf).-2010.-No. 72.- P.377–382.
Katznelson L., Atkinson JL, Cook D., et al. American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly – 2011 update: executive summary // EndocrPract.- 2011.- 17 (4).-P. 636–46.
Negmatova GS, Toshimova GT daughter, Abdiyev LS son, Daminov AT. EFFECTIVENESS OF CORRECTION OF DYSLIPIDEMIA IN ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS. Educational Research in Universal Sciences. 2024;3(1 SPECIAL):269-274.
Pinto EM, Bronstein MD Molecular aspects of pituitary tumorigenesis // Arq Bras EndocrinolMetabol. - 2008. - No. 52. – R.599–610.
Ribeiro-Oliveira A, Jr, Barkan A. The changing face of acromegaly—advances in diagnosis and treatment. Nat Rev Endocrinol. 2012;8(10):605–611. doi: 10.1038/nrendo.2012.101.
Sabino SM, Miranda PA, Ribeiro-Oliveira A., Jr Growth hormone-secreting pituitary adenomas: from molecular basis to treatment options in acromegaly. Cancer BiolTher. 2010;9(7):483–492. doi: 10.4161/cbt.9.7.11581.
Schneider HJ, Kosilek RP, Gunther M, Roemmler J, Stalla GK, Sievers C, Reincke M, Schopohl J, Wurtz RP. A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification. J ClinEndocrinol Metab. 2011;96(7):2074–2080. doi: 10.1210/jc.2011-0237.
SzczesniakD, Jawiarczyk-PrzybylowskaA, RymaszewskaJ. Quality of life and psychological, social and cognitive functioning of patients with acromegaly. AdvClinExp Med. 2015;24(1): 167-172.] (in Russ).
Takhirovich DA, Corners SJA, Shukhratovna NG, Shukhratovna SG, Zaynuddinovna MG. COURSE OF COVID-19 IN PATIENTS WITH DIABETES MELLITUS. Web of Scientist: An International Journal of Scientific Research. 2022;3(02):73-76. doi:10.17605/OSF.IO/B6FU2
Tjörnstrand A., Gunnarsson K., Evert M., Holmberg E., Ragnarsson O., Rosén T., FilipssonNyström H. The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011 // Eur J Endocrinol. - 2014. - No. 171 (4). – R. 519–526.
Wolfsberger S., Wunderer J., Zachenhofer I., Czech T. et al. Expression of cell proliferation markers in pituitary adenomas – correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. // Acta Neurochir (Wien). - 2004. - No. 146. – R. 831–9.
Shukhratovna NG, Shukhratovna SD. Features of the course of autoimmune hepatitis in children as a variant of autoimmune polyglandular syndrome. Asia Journal of Multidimensional Research (AJMR). 2020;9(7):89. doi:10.5958/2278-4853.2020.00228.1
Erkinovna SD. Features of the Course of Diabetes Mellitus Type 2 with Arterial Hypertension.JournalNX. Published online 2020:460-461.
Negmatova GS, Khakimova GD daughter, Abdiyev LS son, Daminov AT. FEATURES OF THE RULES FOR INSULIN INJECTION TECHNIQUES IN ELDERLY AND SENILEPATIENTS WITH DIABETES MELLITUS. Educational Research in Universal Sciences. 2024;3(1 SPECIAL):259-264.
Takhirovich DA, Zafarovna KM, Israilovna IS. FEATURES OF TYPE 1 DIABETES IN CHILDREN WHO HAVE COVID-19.American Journal of Pediatric Medicine and Health Sciences (2993-2149). 2023;1(9):121-123.
Ismailov JA, Egamberdiyeva YK, Mahmamuradova NN, Daminov AT. FEATURES OF VITAMIN-D METABOLISM IN PATIENTS WITH DIABETIC NEPHROPATHY.Educational Research in Universal Sciences. 2024;3(4 SPECIAL):681-689.
Khudoyorov S, Mirkomilova M, Burkhanov U, Sayfieva G, Sheralieva N, Daminov AT. Fournier's gangrene in modern conditions.Science and Education. 2023;4(12):107-117.
Alimovna KN, Sobirjanovna KN, Abdurasul D, Tulkinovich OS. GROWTH HORMONE FOR THE TREATMENT OF HEREDITARY DISEASES IN CHILDREN. 10.
Negmatova .G.Sh, De S, Kyzi MZO, Mannobovich MS, Orifjonovich MM. HERPETIC MENINGITIS.EDUCATOR. 2022;5(5):346-348.
Ahrorbek N, Myungjae L, Jungjae L, et al. Hormonal regulation.Texas Jour of Mutl Stud. 2023;25:39-43.
Ismailova SI Impact of vitamin D deficiency on the risk of developing type 1 diabetes.ScienceandEducation. 2023;4(3).
Daminov AT, Khakberdieva V, Zhanikulov S, Murodkhonov S. CLINICAL CASE OF PRIMARY HYPOTHYROIDSIS. EducationalResearchinUniversalSciences. 2024;3(3 SPECIAL):131-134(in Russ).
Mizamova MAK, Eshpulatova GNK, Eshmurodova ZNK, Salimova DE. Health-related complications of acromegaly, current and promising treatment options.Science and Education. 2023;4(4):187-195(in Russ).
Takhirovich DA, Zafarovna KM, Israilovna IS. ENDOCRINE CHANGES IN NEUROLOGY.LATEST SCIENTIFIC RESEARCH THEORY. 2023;6(12):417-422(in Uzb).
Ismailov JA, Egamberdiyeva YK, Mahmamuradova NN, Daminov AT. PRETIBIAL MYXEDEMA: PATHOGENETIC FEATURES AND CLINICAL ASPECTS.Educational Research in Universal Sciences. 2024;3(4 SPECIAL):695-702.
Negmatova GS, Salimova DE. SugaryCharacteristics of type 2 diabetes with arterial hypertension and methods of treatment. Science and Education. 2023;4(2):516-519(in UZB).
Takhirovich DA, JT, OE, I A. ASSESSMENT OF THE DYNAMICS OF THE TREATMENT OF COVID-19 DISEASE WITH GLUCOCORTICOIDS IN PATIENTS WITH TYPE 2 DIABETES.Gospodarka i Innowacje. 2023;34:78-81(in UZB).
G.Sh N, De S, Alisherovich BA, Erkin R is the son of S, Bektash U is the son of S. RELATIONSHIP BETWEEN DIABETIC NEPHROPATHY AND CARDIAC DISORDERS IN PATIENTS WITH TYPE 2 DIABETES.EDUCATOR. 2022;5(5):337-340.
Daminov AT, Sadullayeva SM girl, Ismailova SI girl. FREQUENCY OF COMPLICATIONS OF DIABETES IN SAMARKAND REGION.Educational Research in Universal Sciences. 2024;3(3 SPECIAL):139-142(in UZB).
Shukhratovna NG, Erkinovna SD, Son IBI, Daughter ADD. THE ROLE OF GASTROINTESTINAL HORMONES IN THE PATHOLOGY OF THE DIGESTIVE SYSTEM.EDUCATOR. 2022;5(6):408-412.
Ulugbekovna NP, Bakhtiyorovna RI, Almosovich RA, Takhirovich DA. Thyroid Diseases during Pregnancy and their Impact on Maternal and Fetal Outcomes.American Journal of Pediatric Medicine and Health Sciences (2993-2149). 2023;1(8):188-190.
Ismailov JA, Egamberdiyeva YK, Mahmamuradova NN, Daminov AT. TIME-RESTRICTED NUTRITION AS A NEW STRATEGY FOR THE THERAPY OF OBESITY AND COMORBID CONDITIONS.Educational Research in Universal Sciences. 2024;3(4 SPECIAL):660-667.
Takhirovich DA, Nasimova D, Khushvaktova B, Aliyeva N, Mirabror B. QUALITY OF MEDICAL CARE PROVIDED TO CHILDREN WITH TYPE 1 DIABETES MELLITUS.EDUCATOR. 2024;7(3):16-22.
Kholdorov X, Omonov F, Jumayev I, Daminov AT. TYPE 1 DIABETES AS A RISK FACTOR FOR BONE HEALTH IN CHILDHOOD.Results of National Scientific Research International Journal. 2023;2(8):131-135.
Daminov AT, Khurramova S, Islamov A, Ulashev M, Ikramov R, Mirzakhakimov P. Type 2 diabetes and bone mineral density in postmenopausal women.Science and Education. 2023;4(11).
Berkinov A, Safarov F, Tursunova S, Daminov AT. VITAMIN D STATUS IN SENIOR RESIDENTS OF SAMARKAND REGION.Results of National Scientific Research International Journal. 2023;2(8):136-140.
Takhirovich DA, Ulugbekovna RN, Abdukhalimova YJ. STATUS AND PROSPECTS FOR THE FIGHT AGAINST DIABETES MELLITUS.Educational Research in Universal Sciences. 2024;3(1):4-9.
Davranova A. CHARACTERISTICS OF MENSTRUAL DISORDER IN TEENAGE GIRLS WITH THYROID GLAND PATHOLOGY. Eurasian Journal of Medical and Natural Sciences. 2022;2(8):113-115(in UZB).
Статья поступила в редакцию 10.05.2024; одобрена после рецензирования 21.06.2024; принята к публикации 29.06.2024.
The article was submitted 10.05.2024; approved after reviewing 21.06.2024; accepted for publication 29.06.2024.
Информация об авторах:
Холикова Адлия Омонуллаевна - к.м.н., Заведующая отделением нейроэндокринологии, Республиканский специализированный научно-практический медицинский центр эндокринологии имени академика Ё.Х.ТУРАКУЛОВА, Ташкент, Узбекистан. Е-mail: info@endomarkaz.uz, ORCID ID: 0009-0006-5327-4322.
Халимова Замира Юсуфовна - д.м.н., профессор Заместитель директора по научной работе и подготовке кадров, Республиканский специализированный научно-практический медицинский центр эндокринологии имени академика Ё.Х.ТУРАКУЛОВА, Ташкент, Узбекистан. Е-mail: info@endomarkaz.uz, ORCID ID: 0000-0002-3041-0268.
Мавлянова Гулхида - Врач Эндокринолог-реаниматолог, Отделение реанимации и интенсивной терапии, Республиканский специализированный научно-практический медицинский центр эндокринологии имени академика Ё.Х.ТУРАКУЛОВА, Ташкент, Узбекистан. Е-mail: info@endomarkaz.uz, ORCID ID: 0009-0005-8673-2601.
Негматова Гулзода Шухратовна- PhD, Заведующая кафедрой Эндокринологии, Самаркандский государственный медицинский университет, Самарканд, Узбекистан. Е-mail: gulzoda2111@ gmail.com, https://orcid.org/0009-0003-4750-7765
Источники финансирования: Работа не имела специального финансирования.
Конфликт интересов: Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Вклад авторов:
Холикова А.О., Халимова З.Ю. — идеологическая концепция работы, написание текста; редактирование статьи;
Мавлянова Г., Негматова Г.Ш. — сбор и анализ источников литературы, написание текста.
Information about the authors:
Kholikova Adlia Omonullaevna - Candidate of Medical Sciences, Head of the Department of Neuroendocrinology,Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Y.Kh. TURAKULOV, Tashkent, Uzbekistan. E-mail:info@endomarkaz.uz, ORCID ID: 0009-0006-5327-4322.
Khalimova Zamira Yusufovna - Doctor of Medical Sciences, ProfessorDeputy Director for Scientific Work and Personnel Training, Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Y.Kh. TURAKULOV, Tashkent, Uzbekistan. E-mail:info@endomarkaz.uz, ORCID ID: 0000-0002-3041-0268.
Mavlyanova Gulkhida Umardjanovna -Endocrinologist-reanimatologist, Department of Reanimation and Intensive Care, Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Y.Kh. TURAKULOV, Tashkent, Uzbekistan. E-mail:info@endomarkaz.uz, ORCID ID: 0009-0005-8673-2601.
Negmatova Gulzoda Shukhratovna - PhD, Head of the Department of Endocrinology, Samarkand State Medical University, Samarkand, Uzbekistan. E-mail:gulzoda2111@gmail.com, https://orcid.org/0009-0003-4750-7765
Sources of financing:The work did not have special funding.
Conflict of interest: The authors declare that there are no obvious or potential conflicts of interest related to the publication of this article.
Authors' contributions:
Kholikova A.O., Khalimova Z.Yu. — ideological concept of the work, writing the text; article editing;
Mavlyanova G., Negmatova G.Sh. — collection and analysis of literature sources, writing text.
